Dermata Therapeutics (DRMA) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Dermata Therapeutics in October 2026.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Dermata Therapeutics (DRMA) Stock Forecast
Analyst price target, next 12 months
$7.00
+533.5% vs today's $1.11
Price range over the last 12 months
Close to its 12-month low
Analysts covering Dermata Therapeutics have a consensus 12-month target of $7.00, above the current price of $1.11.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Dermata Therapeutics' stock with a target price of $7, indicating strong potential growth.
Financial Health
Dermata Therapeutics is managing its finances reasonably well, showing positive cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
